Influenza vaccines are important to public health because they help reduce respiratory disease and death. It was over 10 years ago that the Centers for Disease Control and Prevention made a universal recommendation for seasonal influenza. Since then, real-world vaccine effectiveness (VE) studies have been conducted to help assess the outcome of this recommendation. These studies have shown the potential for VE to fluctuate, impacting confidence in influenza vaccines. Egg-adaptation has contributed to low VE and with the availability of cell-based and enhanced vaccines, there is the potential to address VE concerns.
This panel seeks to discuss the use of real world data to help define what is a “good” level of VE for influenza vaccines. It also challenges the notion that efficacy studies, required by the Food and Drug Administration, provide the complete picture for influenza vaccines given strain variability, and can create information gaps in decision-making.
Ability Level: All
Session ID: 503581